Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report

Triple negative breast carcinoma is a problematic subtype with poor outcomes. Many clinical trials are underway to find possible target to increase treatment options. Epidermal growth factor receptor (EGFR) has emerged as one such molecule which is over expressed in some of these patients and can be...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Gunjesh Kumar, Bajpai, Jyoti, Joshi, Shalaka, Prabhash, Kumar, Choughule, Anuradha, Patil, Asawari, Gupta, Sudeep, Badwe, Rajendra Achyut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498275/
https://www.ncbi.nlm.nih.gov/pubmed/33014134
http://dx.doi.org/10.3332/ecancer.2020.1092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498275/
https://www.ncbi.nlm.nih.gov/pubmed/33014134
http://dx.doi.org/10.3332/ecancer.2020.1092

Ejemplares similares